type in your search and press enter
U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy
You May Also Like
Key Opinion Leader Management – Global Industry Analysis and Opportunity Assessment by 2026 | Future Market Insights
Valley Cottage, NY, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Key opinion leaders (KOLs) are ...
Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
SALT LAKE CITY, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary ...
